This document discusses principles of pharmacoeconomics and their impact on pharmaceutical research and development. It describes how pharmacoeconomic evaluations measure health gains and costs to compare medical procedures. Randomized controlled trials are required to prove efficacy and safety, but real-world studies are also needed to evaluate long-term health benefits and costs. Economic modeling can be used alongside clinical trials to estimate benefits like quality-adjusted life years to determine appropriate pricing and reimbursement strategies for new drugs. Understanding pharmacoeconomics principles is important for pharmaceutical R&D decision making.
Drug distribution is one of the basic service provided by the hospital pharmacy.
Drug distribution system falls in to 3 categories -
1)Ward – controlled system
2)Pharmacy controlled imprest based system
3)Pharmacy controlled patient issue system
Drug distribution is one of the basic service provided by the hospital pharmacy.
Drug distribution system falls in to 3 categories -
1)Ward – controlled system
2)Pharmacy controlled imprest based system
3)Pharmacy controlled patient issue system
Clinical pharmacokinetics and its application--
1)definition
2) APPLICATIONS OF CLINICAL PHARMACOKINETICS
Design of dosage regimens:
a) Nomograms and Tabulations in designing dosage regimen,
b) Conversion from intravenous to oral dosing,
c) Determination of dose and dosing intervals,
d) Drug dosing in the elderly and pediatrics and obese patients.
Pharmacokinetics of Drug Interaction:
a) Pharmacokinetic drug interactions
b) Inhibition and Induction of Drug metabolism
c) Inhibition of Biliary Excretion.
Therapeutic Drug monitoring:
a) Introduction
b) Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs).
c) Indications for TDM. Protocol for TDM.
d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy.
e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations
Dosage adjustment in Renal and Hepatic Disease.
a. Renal impairment
b. Pharmacokinetic considerations
c. General approach for dosage adjustment in renal disease.
d. Measurement of Glomerular Filtration rate and creatinine clearance.
e. Dosage adjustment for uremic patients.
f. Extracorporeal removal of drugs.
g. Effect of Hepatic disease on pharmacokinetics.
Population Pharmacokinetics.
a) Introduction to Bayesian Theory.
b) Adaptive method or Dosing with feedback.
c) Analysis of Population pharmacokinetic Data
Hospital Formulary - presentation gives the detail idea about Hospital formulary, its advantage, disadvantage, how to prepare Hospital formulary and much more. this will be useful for Pharm.D-IV YEAR students, which was in their Hospital pharmacy subject. regards APOLLOJAMES
REVIEWING THE CLINICIANS PRESCRIPTION AND TREATMENT PROGRESSION IS THE FUNDAMENTAL RESPONSIBILITY OF PHARMACIST. THIS PRESENTATION WILL DEAL WITH VARIOUS ASPECTS OF REVIEWING PATIENT DRUGTHERAPY PLAN
Clinical pharmacokinetics and its application--
1)definition
2) APPLICATIONS OF CLINICAL PHARMACOKINETICS
Design of dosage regimens:
a) Nomograms and Tabulations in designing dosage regimen,
b) Conversion from intravenous to oral dosing,
c) Determination of dose and dosing intervals,
d) Drug dosing in the elderly and pediatrics and obese patients.
Pharmacokinetics of Drug Interaction:
a) Pharmacokinetic drug interactions
b) Inhibition and Induction of Drug metabolism
c) Inhibition of Biliary Excretion.
Therapeutic Drug monitoring:
a) Introduction
b) Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs).
c) Indications for TDM. Protocol for TDM.
d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy.
e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations
Dosage adjustment in Renal and Hepatic Disease.
a. Renal impairment
b. Pharmacokinetic considerations
c. General approach for dosage adjustment in renal disease.
d. Measurement of Glomerular Filtration rate and creatinine clearance.
e. Dosage adjustment for uremic patients.
f. Extracorporeal removal of drugs.
g. Effect of Hepatic disease on pharmacokinetics.
Population Pharmacokinetics.
a) Introduction to Bayesian Theory.
b) Adaptive method or Dosing with feedback.
c) Analysis of Population pharmacokinetic Data
Hospital Formulary - presentation gives the detail idea about Hospital formulary, its advantage, disadvantage, how to prepare Hospital formulary and much more. this will be useful for Pharm.D-IV YEAR students, which was in their Hospital pharmacy subject. regards APOLLOJAMES
REVIEWING THE CLINICIANS PRESCRIPTION AND TREATMENT PROGRESSION IS THE FUNDAMENTAL RESPONSIBILITY OF PHARMACIST. THIS PRESENTATION WILL DEAL WITH VARIOUS ASPECTS OF REVIEWING PATIENT DRUGTHERAPY PLAN
Pharmacoeconomics is a branch of health economics which compares the value of one drug or a drug therapy to another.
By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better decisions regarding the use of pharmaceutical products and services.
An impactful approach to the Seven Deadly Sins you and your Brand should avoid on Social Media! From a humoristic approach to a modern-life analogy for Social Media and including everything in between, this deck is a compelling resource that will provide you with more than a few take-aways for your Brand!
How People Really Hold and Touch (their Phones)Steven Hoober
For the newest version of this presentation, always go to: 4ourth.com/tppt
For the latest video version, see: 4ourth.com/tvid
Presented at ConveyUX in Seattle, 7 Feb 2014
For the newest version of this presentation, always go to: 4ourth.com/tppt
For the latest video version, see: 4ourth.com/tvid
We are finally starting to think about how touchscreen devices really work, and design proper sized targets, think about touch as different from mouse selection, and to create common gesture libraries.
But despite this we still forget the user. Fingers and thumbs take up space, and cover the screen. Corners of screens have different accuracy than the center. It's time to re-evaluate what we think we know.
Steven reviews his ongoing research into how people actually interact with mobile devices, presents some new ideas on how we can design to avoid errors and take advantage of this new knowledge, and leaves you with 10 (relatively) simple steps to improve your touchscreen designs tomorrow.
You are dumb at the internet. You don't know what will go viral. We don't either. But we are slighter less dumber. So here's a bunch of stuff we learned that will help you be less dumb too.
What 33 Successful Entrepreneurs Learned From FailureReferralCandy
Entrepreneurs encounter failure often. Successful entrepreneurs overcome failure and emerge wiser. We've taken 33 lessons about failure from Brian Honigman's article "33 Entrepreneurs Share Their Biggest Lessons Learned from Failure", illustrated them with statistics and a little story about entrepreneurship... in space!
Pharmacoeconomics is essential to reduce burden for patients in the terms of cost and improve the therapeutic effectiveness by selecting alternative treatments. Physician and pharmacist plays an important role in selecting drugs and treatment alternatives. So, proper selection helps to minimize the cost of therapy in patients. Research studies on pharmacoeconomics helps to know the burden of patients paying for their illness.
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsCognizant
Driven partly by regulatory pressure, stakeholders in the healthcare ecosystem—including payers and patients—now want real-world evidence (RWE) about wellness to supplement and expand randomized control trial (RCT) input from pharmas about pharmaceuticals' efficacy and effectiveness.
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
Outcomes, health economics and pharmacoeconomicsDureshahwar khan
Pharmacoeconomics can be regarded as a branch of health economics which deals with identifying, measuring, and comparing the costs and consequences of pharmaceutical products and services. Some of the concepts involved in pharmacoeconomic analysis include cost minimization, cost effectiveness, cost benefit, and cost utility analysis.
This presentation explains the main features of medicines which will be developed and authorised via the adaptive pathways. It provides a definition of real world evidence and the caveats associated with the use and analysis of real world evidence in drug development.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Principles of Pharmacoeconomics and Their Impact on Strategic Imperatives of Pharmaceutical Research and Development
1. Principles of Pharmacoeconomics and
Their Impact on Strategic Imperatives of
Pharmaceutical Research and
Development
*G.Aasritha William,
Pharm-D
2. INTRODUCTION:
The registration criteria for pharmaceuticals are
strict, the efficacy and safety of new medicines have
to be proven in Randomized Controlled Trials(RCTs).
In the case of some pharmaceuticals, the
intermediate or surrogate health benefit observed in
pivotal clinical trials eventually does not result in
survival and/or clinically meaningful quality-of-life
(QoL) benefit in real-world situations.
When the application of a pharmaceutical therapy
does not result in benefit in real world, health care
resources are wasted. To minimize this welfare loss,
societies need an objective list of health care
technologies with real-world health benefit.
3. Classification of Pharmacoeconomic Evaluations
According to the Measurement of Health Gain
Type of
evaluation
Measurement of
health gain
Measurement of
costs
Applicability
Cost-minimization
analysis
Non-specified (equal
health gain)
Monetary value Comparison of medical
procedures with equal
health gain
Cost-effectiveness
analysis
Natural units (traditional
clinical trial end points)
Monetary value Comparison of medical
procedures with non-
equal health gain
measurable in the same
health dimension
Cost-utility analysis Quality-adjusted life-
years
Monetary value Comparison of any
medical procedures
Cost-benefit
analysis
Monetary value Monetary value Comparison of any
medical and non-medical
procedures and
investment options
4. Classification of Economic evaluations
according to the method of data collection
Type Advantages Disadvantages
Economic
evaluation
alongside clinical
trials
*Randomization (internal
validity)
*Low cost of economic
data collection *Economic
results are available
before reimbursement
decisions
*Selected patient
population
*Limited time horizon
*Monitoring of economic
data is less strict than of
clinical variables
*Calculation of statistical
power is based on efficacy
end points
5. Type Advantages Disadvantages
Naturalistic
Pharmacoecon-
omic studies
*Non-selected ordinary
patients in routine care
settings (external validity)
*Real-world resource
utilization and costs
independent from the
study protocol
*Easy monitoring if
individual patient records
in payers or managed
care database can be
linked based upon
individual patient ID
*Large patient
population.
*Unpredictable data
collection *Limited
time horizon
*Economic results
available only after
reimbursement decisions
6. Type Advantages Disadvantages
Economic
modelling on the
basis of
prospectively
collected clinical
trial data
*Economic modelling
results available before
major decisions
(e.g.reimbursement)
*Generalizable results
*Adjusted to local
medical practice and
patient population.
____
7. IMPACT OF PHARMACOECONOMICS IN
PHARMACEUTICAL R&D:
• For registration purposes, innovators have to prove that the efficacy of the
investigational medical product meets the requested threshold in RCTs, its
risk/benefit ratio is acceptable and its quality is permanent.
Achieved with
cheap,quick and low-risk
clinical programme
Simple clinical trials
with suboptimal
comparators support
these objectives.
Innovators should
prove that new
product is worth
public financing
against the most
widely used
alternative
procedures
Longer and expensive clinical
trials; greater sample size
required.
Evidences for
reimbursement
and formulary
listing
Evidence for
Registration
8. USE OF ECONOMIC MODELLING FOR STRATEGIC
PRICING OF PHARMACEUTICALS:
Pricing of new pharmaceuticals has been constantly challenged by
payers and economists.The optimal price for the company and
their shareholders may not be acceptable for the society.
The question,
‘What is the highest price I can charge for this product?’ is wrong
The right question is,
‘What pricing strategy meets the business objectives of the
company or the product?’ or
‘What price results in fast reimbursement or formulary listing in
major markets?’
The economic value of new medications can be calculated based
upon the comparator price and the differential value. The
comparator is usually the most likely gold standard therapy at
the time of the expected launch of the product.
9. Economic value of a new
immunosuppressive medicine
Economic
value
= Comparator
price
+ Differential
value
Savings Clinical
benefits
Survival/
QoL benefits
Value in use
-Hospitalisation
-Cost of switching
-Chronic rejection
-Graft survival
-Patient survival
-Cost per life year
saved
-Cost per quality
adjusted life year
saved
-Compliance
-Predictability
-Therapeutic dosing
-Productivity of
patients
10. Economic value of a new immunosuppressive
medicine-a theoretical example
The incidence of some adverse events may be reduced while
other events are more frequent; in our example, a net positive
balance for avoided serious adverse event is depicted. Finally,
each society is willing to pay a certain amount for QALY benefits.
11. CONCLUSION
Health care resources available for medical procedures,
including pharmaceuticals, are limited all over the
world. Economic evaluations help to alleviate the
burden of scarce resources by improving the
allocative efficiency of health care
financing.Professionals in the pharmaceutical R&D
process have to be familiar with the principles of
pharmacoeconomics.
In addition to supporting reimbursement claims,
economic modelling may also contribute to ‘go-no-
go’ decisions (including business development and
licensing), selecting the order of target indications
and strategic pricing of new drugs.
12. REFERENCES
• Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Basic types
of economic evaluation. In: Drummond MF, O'Brien BJ, Stoddart GL,
Torrance GW, editors.Methods for the Economic Evaluation of
Health Care Programmes. New York: Oxford University Press; 1997.
pp. 6–26.
• Fox DM, Leichter HM. State model: Oregon. The ups and downs of
Oregon's rationing plan. Health Aff (Millwood) 1993;12:66–70.
• Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using
real-world data for coverage and payment decisions: the ISPOR
Real-World Data Task Force Report.Value Health. 2007;10:326–335.
• Hlatky MA, Owens DK, Sanders GD. Cost-effectiveness as an
outcome in randomized clinical trials. Clin Trials. 2006;3:543–551.